155. Lancet and Statin in the Elderly

155. Lancet and Statin in the Elderly


https://www.clinicalkey.com/#!/content/journal/1-s2.0-S0140673620322339?scrollTo=%23hl0000424

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32233-9/fulltext

do statins work in old people?? This study in the lancet says-

“In a contemporary primary prevention cohort, people aged 70–100 years with elevated LDL cholesterol had the highest absolute risk of myocardial infarction and atherosclerotic cardiovascular disease and the lowest estimated NNT in 5 years to prevent one event.’

researchers calculated that 80 adults aged 80–100 years — would need to receive a moderate-intensity statin for 5 years to prevent one MI.
and145 adults aged 70–79 years — would need to receive a moderate-intensity statin for 5 years to prevent one MI.
and to prevent just one ASCVD event, the numbers needed to treat were 42 and 88, respectively.

But anytime you read the results you have to say “how did you come up with that number” what were your methods?

In this study they took a sample of people from a large Danish database and these were low risk individuals not on statin therapy. They calculated the number of reduced events by calculating the event rate they expected and dividing it by the number of events during the follow up.

But remember youi have to ask how did you come up with your calculation???

“For these calculations, we assumed 30% and 22% relative risk reduction of myocardial infarction and atherosclerotic cardiovascular disease, respectively, per 1·0 mmol/L reduction in LDL cholesterol in individuals free of atherosclerotic cardiovascular disease, as observed in the Cholesterol Trialist Collaboration meta-analyses.”

THIS IS FRUSTRATING because if you have read the cholesterol trialist you collaboration you know that the individuals in the studies were HONDA they were not low risk individuals. The higher the risk you are the more likely a drug is to work. Think about it like this a statin is more likely to work on someone who is really high risk because they are way more likely to have a MACE. Just like breast cancer chemo therapy is more likely to work on someone who has breast cancer and is even more likely to work if the person is a women.

So in this study they estimated the event rate based on really sick people and then said based on that we can say the likelihood for benefit in these more healthy patients would have a benefit or NNT of 42 or 80 to prevent just one MACE.

NOOOOO you cant take the odds of sick people or people with breast cancer and then say well look how it worked in them so it must work the same way in this population over here.


Do the trial of statins in the elderly or don’t publish the paper

Avsnitt(385)

Episode 262: 261. Are Combined Oral Contraceptives Effective for Treating Acne?

Episode 262: 261. Are Combined Oral Contraceptives Effective for Treating Acne?

At ~24 weeks, ~80-90% of females report improvement in their acne with COCs, compared to 50-80% placebo, and 30-50% will have clear-almost clear skin versus 10-40% on placebo. Efficacy appears similar...

2 Apr 20249min

Episode 260: QM on Spring Break

Episode 260: QM on Spring Break

QM on Spring Break-- but do you like the new format? Andrewbuelt@gmail.com

20 Mars 202452s

Episode 261: 260. SGLT2 Summary Recap

Episode 261: 260. SGLT2 Summary Recap

Diabetic patient- Empagliflozin prevents death from cardiovascular causes: NNT 46 per 3.1 yrs ($600 a month, 1 million dollars per life saved)-HFpEF- SGLT2 inhibitors do not prevent death and cost rou...

19 Mars 20246min

Episode 259: 259. EMPULSE Trial- Empagliflozin and Win Ratios

Episode 259: 259. EMPULSE Trial- Empagliflozin and Win Ratios

These findings indicate that initiation of empagliflozin in patients hospitalized for acute heart failure is well tolerated and results in significant clinical benefit in the 90 days after starting tr...

18 Mars 20249min

Episode 258: 258. SOLOIST-WHF -- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Episode 258: 258. SOLOIST-WHF -- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Primary Outcome: Composite of deaths from cardiovascular causes or hospitalizations and urgent visits for heart failureDeath was not improved!NNT of 5 for hospitalizations and urgent visits -- However...

15 Mars 20249min

Episode 257: 256. EMPEROR-Reduced- Cardiovascular Outcomes with Empagliflozin in Heart Failure

Episode 257: 256. EMPEROR-Reduced- Cardiovascular Outcomes with Empagliflozin in Heart Failure

NNT of 20 to prevent 1 hospitalization at 16 months of follow upThey composite outcome was driven by decrease hospitalizations NOT deathhttps://www.nejm.org/doi/full/10.1056/NEJMoa2022190

14 Mars 20249min

Episode 256: 256. DAPA-HF- Dapagliflozin and Heart Failure with Reduced Ejection Fraction - DAPA-HF

Episode 256: 256. DAPA-HF- Dapagliflozin and Heart Failure with Reduced Ejection Fraction - DAPA-HF

NNT of 21 over 18 months to prevent a composite of worsening heart failure or cardiovascular deathNNT for hospitalization = 27NNT for Cardiovascular Death = 53N Engl J Med 2019; 381:1995-2008

13 Mars 20248min

Episode 255: 255. Dapagliflozin and Heart Failure with Preserved Ejection Fraction

Episode 255: 255. Dapagliflozin and Heart Failure with Preserved Ejection Fraction

Dapagliflozin and HFpEF did happen to improve the composite outcome but this was based mainly on hospitalizations not on death and comes at a big price tag with the NNT around 36 at 2.3yrs. N Engl J M...

12 Mars 202410min

Populärt inom Hälsa

somna-med-henrik
rss-bara-en-till-om-missbruk-medberoende-2
inga-beiga-morsor
rss-jossan-nina
alska-oss
not-fanny-anymore
rss-vuxna-pa-latsas
johannes-hansen-podcast
sexnoveller-deluxe
rss-viktmedicinpodden
angestpodden
sova-med-dan-horning
rss-sjalsligt-avkladd
giggles-med-wiggles
sa-in-i-sjalen
rss-the-house-podcast-3
brottarbroder
rss-beratta-alltid-det-har
rss-basta-livet
vinterpasset